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regression-free rates were 0.86, 0.78, and 0.65, respectively. 
The 5-year, 10-year, and 15-year event-free rates were 0.79, 
0.75, and 0.65, respectively. Four children, whose CAA 
would not have been classified as ‘giant’ based on absolute 
diameters instead of z-scores, had experienced an event 
during follow-up. Conclusion: We found a high percentage 
of children in whom the lumen of giant CAA completely 
normalized. Four children not classified as ‘giant’ based on 
absolute diameters with z-scores of ≥10 experienced a car-
diac event. Hence, the use of z-scores seems to be justified.
Keywords Mucocutaneous lymph node syndrome 
(Kawasaki disease) · Coronary aneurysms · Major cardiac 
event · Myocardial infarction
Introduction
Kawasaki disease (KD) is a pediatric vasculitis of the 
medium-sized arteries [1]. Although its exact origin is still 
Abstract Kawasaki disease (KD) is a pediatric vasculi-
tis. Its main complication is the development of coronary 
artery aneurysms (CAA), with giant CAA at the end of the 
spectrum. We evaluated regression and event-free rates in a 
non-Asian cohort of patients with giant CAA using the cur-
rent z-scores adjusted for body surface area instead of abso-
lute diameters. KD patients with giant CAA (z-score ≥10) 
visiting our outpatient clinic between January 1999 and 
September 2015 were included. Patient characteristics 
and clinical details were extracted from medical records. 
Regression was defined as all coronary arteries having a 
z-score of ≤3. A major adverse event was defined as car-
diac death, myocardial infarction, cardiogenic shock, or 
any coronary intervention. Regression-free and event-free 
rates were calculated using the Kaplan–Meier method. We 
included 52 patients with giant CAA of which 45 had been 
monitored since the acute phase. The 1-, 2-, and 5-year 
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unknown, it is thought to be caused by an infectious agent 
in genetically predisposed children [2]. While the disease 
is self-limiting, complications occur, with coronary artery 
aneurysms (CAA) being the most important one. CAA 
develop in approximately 25% of all untreated patients, 
although the introduction of intravenous immunoglobulins 
(IVIG) as treatment has decreased this percentage substan-
tially [3].
At the extreme end of the spectrum of CAA are giant 
CAA. In Asian cohorts, giant CAA typically do not regress, 
but evidence is scarce in the current era of more standard-
ized treatment protocols. Most studies use cut-offs based 
on absolute diameters instead of z-scores. Z-scores are pre-
ferred as they correct the absolute size in mm for body sur-
face area (BSA) of the child [4].
Persistence of giant CAA causes an increased chance of 
thrombosis within and perfusion abnormalities distal to the 
CAA, potentially inducing ischemia and myocardial infarc-
tion (MI) [5]. Also, the persistence of giant CAA requires 
life-long administration of anticoagulation by low-molecu-
lar-weight heparin or vitamin K antagonists.
In this study, we report on a cohort of patients with giant 
CAA based on z-scores, evaluating regression and cardiac 
complications.
Methods
Study Population and Data Collection
The Academic Medical Centre in Amsterdam (The Neth-
erlands) is a tertiary referral center for patients with KD. 
At our center, we have a multidisciplinary outpatient clinic 
for cardiologic and/or (immunologic) long-term follow-up. 
The cohort of KD patients at out center consists of patients 
who were admitted to our center during the acute phase and 
who are admitted to other hospitals during the acute phase 
and are referred to our center for follow-up.
Patients with KD visiting our outpatient clinic between 
January 1999 and September 2015 were eligible. Patients 
were included if they had giant CAA during the acute 
phase of the disease. For analyses purposes, patients who 
were missed during the acute phase and patients of whom 
no information of the acute phase was available were 
excluded.
We retrospectively extracted clinical details from the 
medical records, i.e., gender, age at disease onset, (in)com-
plete disease presentation, treatment with IVIG including 
the day of first IVIG treatment, IVIG re-treatment, treat-
ment with steroids, aspirin and/or anticoagulation therapy, 
and size of the CAA at initial presentation and during 
follow-up.
Coronary Artery Aneurysms
The CAA status was taken from information in echocardiog-
raphy reports. The highest z-score of the left main coronary 
artery, right coronary artery, or left anterior descending artery 
within the first 6 weeks was chosen in order to specify CAA 
[4, 6]. Giant CAA are defined by a z-score of ≥10 [4]. When 
using the Japanese criteria based on absolute diameters, a 
giant CAA is defined as diameter of ≥8 mm [7].
Outcomes: Regression and Major Adverse Events
During follow-up, z-scores based on echocardiography, 
coronary angiographies (CAG’s), Magnetic Resonance 
Imaging (MRI’s), or Computer Tomography (CT)-scans 
were calculated. Regression was defined as all coronary 
arteries having a z-score of ≤3. CAA were also considered 
to have regressed when only a dilation of the origin of the 
coronary arteries with a z-score of 3 to 3.5 was present.
A major adverse event was defined as cardiac death, MI, 
cardiac arrest or cardiogenic shock, coronary artery bypass 
grafting (CABG), or percutaneous coronary intervention 
(PCI).
Statistical Analysis
Regression
We calculated the number of days until all coronary arter-
ies were regressed as demonstrated by an imaging proce-
dure. If regression did not occur, the follow-up time was 
calculated until the date of the last imaging procedure 
with a maximum of 15 years. A regression-free survival 
curve was then constructed by means of the Kaplan–Meier 
method.
Major Adverse Event
If imaging suggested ischemia or infarction without preced-
ing clinical presentation, the time from diagnosis until the 
date of the imaging was calculated. Patients were censored 
if no event occurred; follow-up time was calculated until 
the last registered imaging procedure with a maximum of 
15  years. We assessed the 5-, 10-, and 15-year event-free 
survival using Kaplan–Meier analysis.
Results
Patient Population
In total, 52 patients with giant CAA visited our outpatient 
clinic. In six patients, KD was missed. These six patients 
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(5 men, 1 woman) presented with cardiac complaints due 
to ischemia and/or MI based on thrombus formation in a 
CAA or stenosis proximal or distal to a CAA. None of the 
patients had signs of atherosclerosis or cardiac disease, 
making KD the most likely cause of their giant CAA. In 
one extra patient, no information about the acute phase of 
the disease was available.
The remaining 45 KD patients had echocardiographic 
examinations within 6 weeks after acute disease onset. 
Patient characteristics and clinical data are shown in 
Table  1. Only 18 (40%) children would have classified 
as having ‘giant’ CAA based on absolute diameters. All 
but one child had been treated with IVIG. Most of them 
were treated with 2  g/kg IVIG in a single gift. Two chil-
dren received 400 mg/kg during 5 days, and in 4 children 
dosing had not been recorded. Apart from a second IVIG 
gift, 11 (25%) children received methylprednisolone, oral 
prednisone, or both successively. Four (10%) children sub-
sequently received either anakinra (IL-1 inhibitor) or inf-
liximab (TNF-α inhibitor) due to IVIG and corticosteroid 
resistance. All children received high-dose aspirin during 
the acute phase followed by the standard low-dose aspirin. 
Twenty-four children received additional anticoagulants 
(low-molecular-weight heparin or vitamin K antagonists). 
Most children not receiving anticoagulants at any point had 
KD in an earlier era. Three children received an additional 
platelet aggregation inhibitor.
In 13 (29%) children, aspirin was discontinued after the 
CAA were considered to have regressed completely. They 
had received aspirin for a median of 17.3  months (Inter-
quartile range, IQR 8.8-151.5 months). None of these chil-
dren experienced a cardiac event during or after discontinu-
ation of aspirin therapy.
Regression of Giant CAA
The 1-, 2-, and 5-year regression-free rates were 0.86, 
0.78, and 0.65, respectively (Fig. 1). Remarkably, in 4 chil-
dren the giant CAA had completely normalized more than 
5  years after the acute phase of the disease. Apart from 
the 9 children with giant CAA going into complete regres-
sion, the largest change in z-score was observed in the first 
2 years with an additional 13 children showing regression 
to medium or small CAA (Fig. 2).
Due to the small number of children and the accompa-
nying lack of power, we could not perform multivariable 
regression analyses to identify predictors for the persis-
tence of giant CAA. Strikingly, only 4 (9%) children were 
girls, of which 2 had completely regressed CAA. A total of 
23 (50%) children were under the age of 1 during the acute 
disease, of which 4 regressed within the first and an addi-
tional 2 within the second year. Of the 22 children over the 
age of 1 during the acute disease, 2 regressed within a year 
and 1 other child within the first 2 years.
Of the 19 children receiving a second IVIG dose, 6 had 
completely regressed CAA in a median time of 2.9 years 
(IQR 1.3–4.4). Of the 11 children receiving subsequent 
steroid treatment, 5 had regressed in a median time of 
4.0 year (IQR 1.2–4.6).
Of the 14 children with an original z-score of 10–15, 
11 (80%) went into complete regression. Of the children 
with an original z-score of 15–20, only 4 (25%) out of 16, 
and for the children with an original z-score of > 20, we 
observed that only 3 (20%) out of 15 completely regressed 
(Supplemental Fig. 1).
Major Adverse Event
A total of 12 cardiac events or interventions took place 
after a median time of 0.17 years (range 0.02–13.58 years) 
(Fig.  3). All events accompanied with clinical symptoms 
occurred within 5 months after the acute disease, and inter-
ventions and subclinical events occurred later. All events 
happened in children with, at that time, non-regressed 
CAA. The 5-, 10-, and 15-year adverse event-free rates 
were 0.79, 0.75, and 0.65, respectively. In 4 children who 
would not have classified for a giant CAA according to 
the absolute diameters, a serious cardiac event took place, 
although significantly more events occurred in children 
with giant CAA based on absolute diameters (p = 0.041).
Two children died as a result of MI. Another 6 children 
experienced MI. At time of the ischemic event, 3 chil-
dren were using vitamin K inhibitors or low-weight hepa-
rin, 3 children were taking aspirin, and in 2 children anti-
platelet therapy had not been initiated (yet). In 3 of them, 
the ischemia was only apparent upon contrast-enhanced 
Table 1  Demographic and clinical characteristics of patients with 
giant CAA during the acute disease
IVIG intravenous immunoglobulins
a Median (interquartile range), + Day calculated from first day of fever
Giant CAA n = 45
Male gender, n (%) 41 (91)
Age at disease onset (years)a 1.0 (0.3–2.8)
Complete disease, n (%) 29 (64)
IVIG treatment, n (%) 44 (98)
Day first IVIG treatment+a 10 (7–18)
Second IVIG treatment, n (%) 19 (42)
Steroid treatment, n (%) 11 (24)
Highest-ever z-scorea 17.1 (14.0–24.1)
Highest-ever diameter (mm)a 6.9 (5.7–8.5)
Follow-up time (years)a 6.9 (2.6–15)
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Fig. 1  Kaplan–Meier estimates 
of regression-free survival of 
patients with giant CAA. + 
Indicates censored patients
Fig. 2  CAA size after 1 and 
2 years. Small CAA z-score 3–5, 
medium CAA z-score 5–10, 
giant CAA ≥10. CAA= coronary 
artery aneurysms
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imaging of the heart as clinical symptoms and cardiac signs 
were absent.
Five children had a cardiac arrest or cardiogenic shock. 
Four children had undergone CABG at a median age of 
15.9 years (range 10.5–22.0 years).
Four of the children who experienced MI obtained a car-
diac MRI with adenosine stress testing during follow-up, 
showing hypo- or akinesia of the wall in the infarcted areas 
but an otherwise good systolic function. Another 15 chil-
dren obtained a MRI with adenosine stress testing, showing 
no functional abnormalities.
Stenosis
In 8 children, coronary arterial stenosis was apparent with 
subsequent CABG in 3 and a coronary balloon dilation in 
1 patient(s). In 2 children, the stenoses became only appar-
ent at autopsy and in 2 children the stenosis did not require 
immediate intervention. Most stenoses were seen directly 
proximal or distal to the CAA. None of these children had 
completely regressed CAA. Five of the children with arte-
rial stenoses had experienced MI. In Table 2, the distribu-
tion of patients with cardiac events and with stenosis is 
shown.
Discussion
In a large Dutch cohort of KD patients with giant CAA 
based on z-scores, visiting our outpatient clinic during a 
15-year period, we calculated 1-year, 2-year, and 5-year 
regression-free rates of 0.86, 0.78, and 0.65. The 5-year, 
10-year, and 15-year event-free rates were 0.79, 0.75, and 
0.65. This is the first study solely evaluating patients with 
giant CAA based on z-scores in a Western population.
A study by Chih at al., following 27 children with giant 
CAA (≥ 8  mm), found that none completely regressed 
Fig. 3  Kaplan–Meier estimates 
of major adverse event-free 
survival of patients with giant 
CAA. Cardiac event- and car-
diac intervention-free survival. 
+ Indicates censored patients
Table 2  Distribution of cardiac events and stenosis in patients with 
giant CAA
CAA coronary artery aneurysms, CABG coronary artery bypass graft-
ing
a 2 children died as a result of MI, + 2 children had stenosis but no 
event
Stenosis + MI MI Stenosis – Total
Cardiac 
arrest/shock
2a 1 – 2 5
CABG 2 – 1 1 4
– 1 2 2+ – 5
Total 5 3 3 3 14
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[8]. In a Taiwanese study evaluating KD patients includ-
ing 27 patients with giant CAA (≥8 mm), the same result 
was found [9]. On the other hand, a recent study review-
ing 90 US patients with giant CAA based on z-scores, 
found that in 19% of the patient with giant CAA regres-
sion occurred [10]. In our study, 18 (40%) children with 
a z-score of ≥ 10 completely regressed. Of these chil-
dren, 50 and 78% of the regression occurred within the 
first 2 and 5 years, respectively. In 4 out of 45 children, 
the z-scores decreased to <3 more than 5 years after dis-
ease onset. The decline of the z-scores in these children 
is suggested to be due to the normal growth of these chil-
dren rather than a decline of the absolute CAA diameter. 
Our finding that regression mainly takes place in the first 
5  years is supported by earlier studies. Lin et  al. found 
a 5-year persistence rate of 46% for medium-sized CAA 
with little regression after [9]. Kato et  al., studying a 
group of patients with CAA of all sizes, found that 90% 
of regression occurred within the first 2 years [11].
In a large Japanese study, Tsuda et  al., studying 245 
patients with giant CAA (≥8  mm), found 10-, 20-, and 
30-year cardiac event-free survival rates of 64, 48, and 
36%, respectively [5]. The aforementioned study by 
Chih et  al. found 10- and 20-year ischemia-free rates of 
52 and 21% [8]. Our study showed higher cardiac event-
free rates, which could partly be the result of the use of 
z-scores instead of absolute diameter cut-off. However, 
4 children, whose CAA would not have been classified 
as ‘giant’ based on absolute diameters, did experience an 
event (cardiac arrest, MI, and cardiogenic shock), which 
suggests that z-scores are helpful in identifying patients 
at high risk. Also, all but one patient in our cohort 
received IVIG, improving outcome as IVIG was found to 
be an independent risk factor for major adverse cardiac 
events (MACE) in a recent study [10].
Most events happened within the first months after 
the acute phase. Yet, in 3 patients, echocardiography or 
MRI showed signs of a small MI or subclinical ischemia, 
10 years or more after the acute disease .Although con-
ventional coronary angiography is still the gold stand-
ard to assess coronary anatomy and possible steno-
sis, this technique is invasive and exposes the child to 
radiation. Low-dose CT angiography is becoming more 
widely available and decreased the radiation burden sig-
nificantly [12]. Using echocardiography or cMRI with 
additional adenosine stress testing, systolic function and 
flow reserve capacity can be evaluated, yet cMRI can-
not be performed in young children without the use of 
anesthesia. The results of these 3 patients suggest that all 
children should be followed up with regular intervals to 
assess vascular flow reserve capacity using a combination 
of these techniques as we proposed previously [13].
Although we only observed cardiac events in chil-
dren with persisting CAA at that time, it is unlikely that 
regression of CAA to a normal diameter of the arterial 
lumen will eliminate all future cardiovascular risk. Even 
if the lumen has a normal diameter, the arterial wall is 
supposed to be damaged and unable to adequately dilate 
upon increased cardiac demand [14]. In a recent study 
using optical coherence tomography, changes in the coro-
nary artery wall structure, especially intimal hyperpla-
sia, were seen in CAA but also in segments where the 
CAA had regressed [15]. This study indicates that these 
patients require life-long follow-up, even if the arterial 
lumen has gone back to normal size. In 13 children of 
our cohort, aspirin therapy was discontinued after the 
CAA were considered to have regressed. Regarding the 
remodeling, persistent damage, and increased stiffness of 
the arterial wall years after the acute phase, it is ques-
tionable whether antiplatelet medication should ever be 
discontinued in patients with regressed giant CAA. How-
ever, none of the children in whom aspirin had been dis-
continued experienced an event. This is in concordance 
with the study by Friedman et  al. who found that none 
of the patients with regressed CAA experienced MACE 
[10]. Stenosis, a result of a remodeling process of the 
artery, only occurred in children with CAA that had not 
completely regressed. In summary, more research is nec-
essary for definite recommendations regarding (life-long) 
aspirin therapy.
Limitations
We calculated z-scores from absolute diameters described 
in echocardiography, CAG-, MRI-, or CT-reports. Since 
approximately half of the patients were admitted to other 
hospitals during the acute phase of the disease, pediatric 
cardiologists in other centers had generated many of the 
early echocardiographies. Echocardiography is known 
for its measurement uncertainty, which could have influ-
enced the regression as well as the time-to-regression.
For the time-to-regression, we registered the time until 
the first imaging procedure that demonstrated normality 
of all coronary arteries. The precise time of regression 
can therefore not exactly be defined. Hence, the time-to-
regression has to be considered as the maximum time in 
which regression took place.
As this was a retrospective study, imaging was not 
performed according to a set protocol. This means sub-
clinical ischemia could have been missed in children if no 
suitable imaging technique was performed.
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Conclusion
In a Dutch cohort of KD patients with giant CAA based 
on z-scores followed up from the acute phase, the 1-, 2-, 
and 5-year regression-free rates were 0.86, 0.78, and 0.65. 
The 5-, 10-, and 15-year major adverse event-free rates 
were 0.79, 0.75, and 0.65, respectively. In 4 children whose 
CAA would not have classified as being ‘giant’ according 
to absolute diameters instead of z-scores, a cardiac event 
took place. Therefore, z-scores are suggested to be a more 
sensitive tool to decide on life-long regular follow-up of 
KD children.
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